AI Article Synopsis
- Ramucirumab is a medication that blocks blood vessel growth and is used to treat advanced gastric and colon cancer.
- Clinical trials indicated a slight increase in blood clot-related issues, like strokes, when using ramucirumab, though these findings weren't statistically significant.
- This text presents one of the first detailed case reports linking ramucirumab to a stroke caused by blood clots forming in situ (in place).
Article Abstract
Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939672 | PMC |
| http://dx.doi.org/10.1159/000446695 | DOI Listing |
Publication Analysis
Top Keywords
vascular endothelial
8
endothelial growth
8
growth factor
8
factor receptor-2
8
case reports
8
case report
4
report ischemic
4
ischemic stroke
4
stroke patient
4
patient metastatic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!